Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Plaque psoriasis affecting at least 8% of the body surface area and scoring 8 or higher in the psoriasis area and severity index
- Exclusion Criteria:
- • Seropositive for infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus; Tuberculosis; Acute systemic infection;
- • Treatment with a monoclonal antibody therapy within 12 weeks prior to study entry;
- • An absolute indication for a known effective treatment
About Biotie Therapies Corp.
Biotie Therapies Corp. is a biopharmaceutical company focused on the development of innovative therapies for neurological and psychiatric disorders. With a commitment to addressing unmet medical needs, Biotie leverages advanced research and development to create novel treatment options, particularly in areas such as addiction, pain, and cognitive impairment. The company emphasizes a patient-centered approach and collaborates with leading research institutions and healthcare professionals to ensure the efficacy and safety of its therapeutic candidates. Through rigorous clinical trials and strategic partnerships, Biotie aims to bring transformative therapies to market, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Dresden, , Germany
Görlitz, , Germany
Leipzig, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials